Cytogen demonstrates benefits of ProstaScint:
This article was originally published in Clinica
Clinical trials of Cytogen's prostate cancer imaging agent, ProstaScint, demonstrate its possible use in selecting patients for salvage pelvic radiotherapy following radical prostatectomies. The indium-111 capromab pendetide compound is scheduled for review by the FDA's Medical Imaging Drug Advisory Committee in July. The New Jersey-based company presented the results of the trials at the AUA meeting.
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.